Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2025)
Historic Non-Current Debt for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $11.9 million.
- Recursion Pharmaceuticals' Non-Current Debt fell 4196.98% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 4196.98%. This contributed to the annual value of $19.0 million for FY2024, which is 162770.21% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Non-Current Debt is $11.9 million, which was down 4196.98% from $14.2 million recorded in Q2 2025.
- Recursion Pharmaceuticals' 5-year Non-Current Debt high stood at $22.9 million for Q2 2024, and its period low was $536000.0 during Q4 2022.
- In the last 5 years, Recursion Pharmaceuticals' Non-Current Debt had a median value of $1.2 million in 2023 and averaged $7.1 million.
- Per our database at Business Quant, Recursion Pharmaceuticals' Non-Current Debt crashed by 9445.42% in 2021 and then soared by 188450.22% in 2024.
- Recursion Pharmaceuticals' Non-Current Debt (Quarter) stood at $633000.0 in 2021, then decreased by 15.32% to $536000.0 in 2022, then soared by 105.41% to $1.1 million in 2023, then soared by 1627.7% to $19.0 million in 2024, then plummeted by 37.43% to $11.9 million in 2025.
- Its Non-Current Debt was $11.9 million in Q3 2025, compared to $14.2 million in Q2 2025 and $16.4 million in Q1 2025.